Sodium stibogluconate

{
  "id": "MLC-T-ONC-007852",
  "term": "Sodium stibogluconate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of certain solid tumors, lymphoma, and myeloma. Sodium stibogluconate may block enzymes needed for cancer growth. It is a type of pentavalent antimonial. Also called SSG.",
    "Pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phophorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis."
  ],
  "abbreviation": "SSG",
  "synonyms": [
    "SSG"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/sodium-stibogluconate/"
}